This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AstraZeneca Loses U.S. Patent Case

A Missouri judge handed European drug giant AstraZeneca (AZN - Get Report) a defeat in a case involving two patents for the hypertension drug Toprol-XL, finding both invalid and unenforceable.

AstraZeneca said it will appeal the ruling. Both patents are due to expire in September 2007.

The patents had been challenged by Andrx (ADRX), KV Pharmaceutical (KV.A) and Eon Labs, a unit of Novartis (NVS - Get Report), who want to sell generic versions of Toprol-XL.

The drug, in addition to treating hypertension, is also used for the long-term treatment of angina pectoris and certain types of heart failure. Andrx believes it may be entitled to 180 days of market exclusivity on the 50 mg strength of generic Toprol-XL. The drug had total U.S. sales of $1.29 billion last year, AstraZeneca said.

Shares of Andrx were rising 4.9% to $17.40 in premarket trading. AstraZeneca's American depositary shares were losing 3.8% to $47.48.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AZN $31.68 0.00%
NVS $95.60 0.00%
AAPL $112.34 0.00%
FB $89.89 0.00%
GOOG $614.34 0.00%

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs